Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Covidien To Sell Specialty Chemicals Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

Covidien To Sell Specialty Chemicals Business

Covidien has entered a definitive agreement to sell its Specialty Chemicals business to an affiliate of New Mountain Capital, for $280 million in cash.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covidien has entered a definitive agreement to sell its Specialty Chemicals business to an affiliate of New Mountain Capital, for $280 million in cash. The decision is part of Covidien’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses.

Covidien’s Specialty Chemicals business, headquartered in Phillipsburg, NJ, manufactures and markets high-purity chemicals and related products and services under J.T.Baker and Mallinckrodt Laboratory Chemicals. These products are used in research and quality control labs, microelectronics, environmental testing labs and universities, and for manufacturing in the pharma/biopharma and other industrial markets. In 2009, sales of the Specialty Chemicals product line were $414 million and for the first six months of fiscal 2010, sales were $216 million.

The transaction, subject to customary closing conditions, is expected to close by the end of fiscal 2010.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters